Mìžnarodnij Endokrinologìčnij Žurnal (May 2016)
Calcitonin, Osteocalcin and Osteopontin in Lung Cancer
Abstract
ackground. Lung cancer markers are low levels of the hormone calcitonin in the blood, and high levels of proteins osteocalcin and osteopontin, connected to each other, reflect the processes of bone metastasis and have a predictive value. Objective: to evaluate blood levels of calcitonin, osteocalcin and osteopontin, the factors determining them, the nature of relationships and prognostic role in bone metastasis at different variants of lung cancer. Materials and methods. The study included 86 patients with lung cancer aged 24 to 80 years (mean 58 years), among whom there were 84 % of men and 16 % of women. Central lung cancer occurred in 81 % of cases, peripheral — in 19 %. Small-cell lung cancer has been detected in 21 % of patients, non-small-cell — in 79 %, including adenocarcinoma — in 38 %, squamous-cell carcinoma — in 35 %, large-cell carcinoma — in 6 %. IIIA stage of neoplastic process was noted in 12 % of cases, IIIB — in 21 %, IV — in 67 %. Results. Lung cancer is accompanied by a decrease of bone-related hormone calcitonin in the blood of 20 % of patients on the background of increased concentrations of tumor markers osteocalcin and osteopontin (in 76 and 79 % of cases, respectively), which is closely associated with morphological variant (small- and non-small-cell), the stage and severity of pathological process, determines the development of compression syndrome, tumor invasion into the chest wall, metastasis in lymph nodes and bones, occurrence of chemoradiotherapy complications in the form of radiation pulmonary fibrosis, pulmonary hypertension and myelodepression, and indicators of osteocalcin- and osteopontinemia are inversely correlated with the duration of life of patients. Conclusions. In lung cancer, calcitonin, osteocalcin and osteopontin are the markers of the severity of the disease, reflect the metastasis of the tumor process in the skeleton and have a predictive value.
Keywords